Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Q2 Sales Dip, But Profit Rises

NEW YORK (GenomeWeb News) - Accelrys yesterday said fiscal second-quarter 2008 revenues fell around 2 percent as R&D spending dropped around 13 percent and profit shot up 75 percent.
Total receipts for the three months ended Sept. 30, 2007, dipped to $19.7 million from $20.2 million year over year.
Second-quarter revenue was impacted by “reduced revenues from de-emphasized products” and was offset in part by “continued growth in the solutions and services surrounding the company’s scientific operating platform product line,” the company said.
Accelrys’ R&D spending decreased to $4.3 million from $4.9 million year over year.
The firm’s net income rose to $1.6 million from $935,000 in the year-ago period.
Accelrys said it had around $64.9 million in cash, cash equivalents, and marketable securities as of Sept. 30.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.